## **CLAIMS**

## What is claimed is:

5

- A method for promoting cardiac tissue repair comprising administering to the cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide.
- 2. The method according to Claim 1 wherein said peptide comprises a thrombin receptor binding domain having the sequence Arg-Gly-Asp-Ala (SEQ ID NO. 1); and a serine esterase conserved sequence.
- The method of Claim 2 wherein the serine esterase conserved sequence comprises
   Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 2).
  - 4. The method of Claim 2 wherein the thrombin derivative peptide comprises the amino acid sequence: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gl y-Gly-Pro-Phe-Val (SEQ ID NO. 3).
- 5. The method of Claim 1 wherein the thrombin derivative peptide consists of the

  amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-CysGlu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 4).
  - 6. The method of Claim 1 wherein the peptide is administered during or following cardiac surgery.
- 7. The method of Claim 1 wherein the peptide is administered by injection into the cardiac tissue.

5

- 8. The method of Claim 1 wherein a sustained release formulation comprising the angiogenic thrombin derivative peptide is administered to the cardiac tissue.
- 9. The method of Claim 8 wherein the sustained release formulation is a polylactic acid/polyglycolic acid microparticles comprising the angiogenic thrombin derivative peptide
- 10. A method of stimulating revascularization comprising administering to cardiac tissue a therapeutically effective amount of an angiogenic thrombin derivative peptide.
- A method of stimulating vascular endothelial cell proliferation in a patient in need of such treatment comprising administering to the patient a therapeutically effective
   amount of an angiogenic thrombin derivative peptide.
  - 12. A method of inhibiting restenosis in a patient following balloon angioplasty, said method comprising administering to the patient a therapeutically effective amount of an angiogenic thrombin derivative peptide.
- 13. The method of Claim 12 wherein the peptide is coated onto a balloon angioplasty catheter.
  - 14. The method of Claim 12 wherein the angiogenic thrombin derivative peptide is administered systemically.
  - 15. The method of Claim 12 wherein the angiogenic thrombin derivative peptide is administered locally to a balloon induced damaged area of a blood vessel.
- 20 16. The method of Claim 12 wherein a stent coated with the angiogenic thrombin derivative peptide is inserted into a blood vessel at a balloon induced damaged area.

- 17. The method of Claim 12 wherein said peptide comprises a thrombin receptor binding domain having the sequence Arg-Gly-Asp-Ala (SEQ ID NO. 1); and a serine esterase conserved sequence.
- The method of Claim 17 wherein the serine esterase conserved sequence comprises
   Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 2).
  - 19. The method of Claim 17 wherein the thrombin derivative peptide comprises the amino acid sequence: Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gl y-Gly-Pro-Phe-Val (SEQ ID NO. 3).
- The method of Claim 12 wherein the thrombin derivative peptide consists of the
   amino acid sequence Ala-Gly-Tyr-Lys-Pro-Asp-Glu-Gly-Lys-Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO. 4).
  - 21. A stent coated with an angiogenic thrombin derivative peptide.
- A method of inhibiting vascular occlusion in a patient, said method comprising administering to the patient a therapeutically effective amount of a thrombin
   derivative peptide.